We provide you with 20 years of free, institutional-grade data for GMAB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of GMAB. Explore the full financial landscape of GMAB stock.
| Reported Date | CIK | Ticker | Type |
|---|
Genmab A/S(NASDAQ:GMAB) 
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye d...
Website: http://www.genmab.com
Founded: 1999
Full Time Employees: 712
CEO: Jan G. J. van de Winkel
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about GMAB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.